share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K:外國發行人報告
美股sec公告 ·  05/14 14:50
Moomoo AI 已提取核心訊息
Cybin Inc., a clinical-stage biopharmaceutical company, announced that its CEO, Doug Drysdale, will participate in a fireside chat at the Alliance Global Partners Healthcare Company Showcase on May 21, 2024. The event, which will be held virtually, is set to feature a live webcast of Mr. Drysdale's presentation at 12:40 p.m. ET. Cybin, known for its focus on developing psychedelic-based treatments for mental health conditions, is currently working on CYB003 and CYB004, investigational compounds for major depressive disorder and generalized anxiety disorder, respectively. The company, founded in 2019, operates across multiple countries including Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The webcast will be accessible online and will also be archived on Cybin's investor relations website.
Cybin Inc., a clinical-stage biopharmaceutical company, announced that its CEO, Doug Drysdale, will participate in a fireside chat at the Alliance Global Partners Healthcare Company Showcase on May 21, 2024. The event, which will be held virtually, is set to feature a live webcast of Mr. Drysdale's presentation at 12:40 p.m. ET. Cybin, known for its focus on developing psychedelic-based treatments for mental health conditions, is currently working on CYB003 and CYB004, investigational compounds for major depressive disorder and generalized anxiety disorder, respectively. The company, founded in 2019, operates across multiple countries including Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The webcast will be accessible online and will also be archived on Cybin's investor relations website.
處於臨床階段的生物製藥公司Cybin Inc. 宣佈,其首席執行官道格·德賴斯代爾將於2024年5月21日參加聯盟全球合作伙伴醫療保健公司展示會上的爐邊談話。該活動將以虛擬方式舉行,將在美國東部時間下午 12:40 通過網絡直播德賴斯代爾先生的演講。Cybin以專注於開發基於迷幻藥的心理健康狀況療法而聞名,目前正在研究 CYB003 和 CYB004,這兩種藥物分別是重度抑鬱症和廣泛性焦慮症的研究化合物。該公司成立於2019年,業務遍及多個國家,包括加拿大、美國、英國、荷蘭和愛爾蘭。該網絡直播將可在線觀看,也將存檔在Cybin的投資者關係網站上。
處於臨床階段的生物製藥公司Cybin Inc. 宣佈,其首席執行官道格·德賴斯代爾將於2024年5月21日參加聯盟全球合作伙伴醫療保健公司展示會上的爐邊談話。該活動將以虛擬方式舉行,將在美國東部時間下午 12:40 通過網絡直播德賴斯代爾先生的演講。Cybin以專注於開發基於迷幻藥的心理健康狀況療法而聞名,目前正在研究 CYB003 和 CYB004,這兩種藥物分別是重度抑鬱症和廣泛性焦慮症的研究化合物。該公司成立於2019年,業務遍及多個國家,包括加拿大、美國、英國、荷蘭和愛爾蘭。該網絡直播將可在線觀看,也將存檔在Cybin的投資者關係網站上。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息